single dose of CNCT19
Phase 2Biologic
single dose of CNCT19 is one of 100 biologic programs targeting Lymphoma. It is currently in Phase 2.
3
Indications
6
Total Trials
4
Active Trials
99
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Blenoxane
SSequus Pharmaceuticals
Preclinical
Velban
EEastern Cooperative Oncology Group
Preclinical
Oncaspar
SServier
Preclinical
single dose of CNCT19
JJuventas Cell Therapy Ltd.
Phase 2
Norvir
AbbViePreclinical
Wellcovorin
GGlaxo Dba Glaxosmithkline
Preclinical
Tafasitamab
IncytePreclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Lymphoblastic Leukemia2 trials
Lymphoma2 trials
Autoimmune Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for single dose of CNCT19. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- JJuventas Cell Therapy Ltd.